We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

The silent treatment

8 September 2005 By Edward Hadas

The 20% drop in halfyear EPS was totally unexpected. Yet the company says there was no need to warn about the interims beforehand. It still expects to make its projected operatingprofit growth for the year. But investors are rightly sceptical.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)